Item 7.01. Regulation FD Disclosure.
On December 14, 2016,
BioScrip, Inc. (the “Company”), in connection with the Company’s intention to seek an amendment (the “Amendment”)
of the Credit Agreement, dated July 31, 2013, as amended (the “Credit Agreement”), will make a presentation to its
lenders under the Credit Agreement, a copy of which is furnished herewith as Exhibit 99.1.
The Company issued
a press release regarding the proposed Amendment and providing a business update. A copy of the press release is furnished herewith
as Exhibit 99.2.
The information
in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that Section. The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be incorporated by reference into
any registration statement or other document pursuant to the Securities Act of 1933, as amended. The Company undertakes no
duty or obligation to publicly update or revise the information contained in this Current Report and cautions that the
information included in this Current Report under Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is current only as of December 14, 2016
and may change thereafter. The furnishing of the information in this report is not intended to, and does not, constitute
a determination or admission by the Company that the information in this report is material or complete, or that
investors should consider this information before making an investment decision with respect to any security of the
Company.
Forward-Looking
Statements
This current report
includes statements that may constitute “forward-looking statements,” that involve substantial risks and uncertainties.
These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can
identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking
statements can be identified by words such as “may,” “should,” “could,” “anticipate,”
“estimate,” “expect,” “project,” “outlook,” “aim,” “intend,”
“plan,” “believe,” “predict,” “potential,” “continue” or comparable
terms. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those
expressed or implied by such forward-looking statements. Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those
in the forward-looking statements as a result of various factors. Important factors that could cause or contribute to such differences
include but are not limited to risks associated with: the Company’s ability to integrate the acquisition of Home Solutions,
the Company’s ability to grow its core Infusion revenues, the Company’s ability to continue to experience positive
results from its financial improvement plan to reduce operating costs; the Company’s ability to consummate the Amendment
and to comply with the covenants in its debt agreements; the success of the Company’s initiatives to mitigate the impact
of the Cures Act on its business; reductions in federal, state and commercial reimbursement for the Company’s products and
services; increased government regulation related to the health care and insurance industries; as well as the risks described in
the Company’s periodic filings with the Securities and Exchange Commission. The Company does not undertake any duty to update
these forward-looking statements after the date hereof, even though the Company’s situation may change in the future. All
of the forward-looking statements in this report are qualified by these cautionary statements.